33 related articles for article (PubMed ID: 24709000)
21. Pharmacokinetics of alemtuzumab and the relevance in clinical practice.
Elter T; Molnar I; Kuhlmann J; Hallek M; Wendtner C
Leuk Lymphoma; 2008 Dec; 49(12):2256-62. PubMed ID: 19052972
[TBL] [Abstract][Full Text] [Related]
22. Rediscovering alemtuzumab: current and emerging therapeutic roles.
Gribben JG; Hallek M
Br J Haematol; 2009 Mar; 144(6):818-31. PubMed ID: 19183194
[TBL] [Abstract][Full Text] [Related]
23. Monoclonal antibodies in the treatment of chronic lymphoid leukemias.
Robak T
Leuk Lymphoma; 2004 Feb; 45(2):205-19. PubMed ID: 15101704
[TBL] [Abstract][Full Text] [Related]
24. Modern Therapies for Idiopathic Inflammatory Myopathies (IIMs): Role of Biologics.
Moghadam-Kia S; Oddis CV; Aggarwal R
Clin Rev Allergy Immunol; 2017 Feb; 52(1):81-87. PubMed ID: 26767526
[TBL] [Abstract][Full Text] [Related]
25. Alemtuzumab in T-cell lymphoproliferative disorders.
Dearden CE; Matutes E
Best Pract Res Clin Haematol; 2006; 19(4):795-810. PubMed ID: 16997184
[TBL] [Abstract][Full Text] [Related]
26. Alemtuzumab in solid organ transplantation and in composite tissue allotransplantation.
Weissenbacher A; Boesmueller C; Brandacher G; Oellinger R; Pratschke J; Schneeberger S
Immunotherapy; 2010 Nov; 2(6):783-90. PubMed ID: 21091110
[TBL] [Abstract][Full Text] [Related]
27. Tropical spastic paraparesis and HTLV-1 associated myelopathy: clinical, epidemiological, virological and therapeutic aspects.
Gessain A; Mahieux R
Rev Neurol (Paris); 2012 Mar; 168(3):257-69. PubMed ID: 22405461
[TBL] [Abstract][Full Text] [Related]
28. T cell depletion of allogeneic stem cell grafts with anti-CD 52 monoclonal antibodies: the Ulm experience from 1983-1999.
Bunjes D
Transfus Sci; 2000 Oct; 23(2):151-62. PubMed ID: 11035276
[No Abstract] [Full Text] [Related]
29. Rationale and efficacy of CD52 targeting in HTLV-1-associated myositis.
Cochereau D; Georgin-Lavialle S; Maisonobe T; Dubourg O; Melboucy-Belkhir S; Hermine O; Aouba A
Joint Bone Spine; 2014 Jul; 81(4):362-5. PubMed ID: 24709000
[TBL] [Abstract][Full Text] [Related]
30. Alemtuzumab in T-cell malignancies.
Dearden CE; Matutes E; Catovsky D
Med Oncol; 2002; 19 Suppl():S27-32. PubMed ID: 12180489
[TBL] [Abstract][Full Text] [Related]
31. Humanized Monoclonal Antibody Alemtuzumab Treatment in Transplant.
Bhowmick M; Auckbarallee F; Edgar P; Ray A; Dasgupta S
Exp Clin Transplant; 2016 Feb; 14(1):17-21. PubMed ID: 26862819
[TBL] [Abstract][Full Text] [Related]
32. The CD52 antigen and development of the CAMPATH antibodies.
Hale G
Cytotherapy; 2001; 3(3):137-43. PubMed ID: 12171721
[No Abstract] [Full Text] [Related]
33. Alemtuzumab in the treatment of chronic lymphocytic leukemia.
Robak T
BioDrugs; 2005; 19(1):9-22. PubMed ID: 15691213
[TBL] [Abstract][Full Text] [Related]
[Previous] [New Search]
